Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics
M. Gerckens (Munich, Germany), K. Schorpp (Neuherberg, Germany), F. Pelizza (Glasgow, United Kingdom), M. Wögrath (Munich, Germany), K. Reichau (Neuherberg, Germany), H. Ma (Neuherberg, Germany), A. Dworsky (Munich, Germany), A. Sengupta (Munich, Germany), M. Stoleriu (Munich, Germany), K. Heinzelmann (Munich, Germany), J. Merl-Pham (Neuherberg, Germany), M. Irmler (Neuherberg, Germany), H. Alsafadi (Lund, Sweden), E. Trenkenschuh (Munich, Germany), L. Sarnova (Prague, Czech Republic), M. Jirouskova (Prague, Czech Republic), W. Frieß (Munich, Germany), S. Hauck (Neuherberg, Germany), J. Beckers (Neuherberg, Germany), N. Kneidinger (Munich, Germany), J. Behr (Munich, Germany), A. Hilgendorff (Munich, Germany), K. Hadian (Neuherberg, Germany), M. Lindner (Salzburg, Austria), M. Königshoff (Pittsburgh, United States), O. Eickelberg (Pittsburgh, United States), M. Gregor (Prague, Czech Republic), O. Plettenburg (Neuherberg, Germany), A. Yildirim (Munich, Germany), G. Burgstaller (Munich, Germany)
Source: International Congress 2022 – New mechanistic insights into acute and chronic interstitial lung disorders
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Gerckens (Munich, Germany), K. Schorpp (Neuherberg, Germany), F. Pelizza (Glasgow, United Kingdom), M. Wögrath (Munich, Germany), K. Reichau (Neuherberg, Germany), H. Ma (Neuherberg, Germany), A. Dworsky (Munich, Germany), A. Sengupta (Munich, Germany), M. Stoleriu (Munich, Germany), K. Heinzelmann (Munich, Germany), J. Merl-Pham (Neuherberg, Germany), M. Irmler (Neuherberg, Germany), H. Alsafadi (Lund, Sweden), E. Trenkenschuh (Munich, Germany), L. Sarnova (Prague, Czech Republic), M. Jirouskova (Prague, Czech Republic), W. Frieß (Munich, Germany), S. Hauck (Neuherberg, Germany), J. Beckers (Neuherberg, Germany), N. Kneidinger (Munich, Germany), J. Behr (Munich, Germany), A. Hilgendorff (Munich, Germany), K. Hadian (Neuherberg, Germany), M. Lindner (Salzburg, Austria), M. Königshoff (Pittsburgh, United States), O. Eickelberg (Pittsburgh, United States), M. Gregor (Prague, Czech Republic), O. Plettenburg (Neuherberg, Germany), A. Yildirim (Munich, Germany), G. Burgstaller (Munich, Germany). Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics. 2787
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|